Teva Pharmaceutical

German Respiratory Devices Market, Forecast to 2025 - Focus on Therapeutic Devices, Diagnostic & Monitoring Devices, Consumables & Accessories | PR Newswire | 5/26/2020

… T Presspart Manufacturing Ltd. 6.14. Hamilton Medical AG 6.15. Koninklijke Philips N.V. 6.16. Medtronic PLC 6.17. Novartis AG 6.18. PMD Device Solutions Ltd. 6.19. ResMed Corp. 6.20. Savara, Inc. 6.21. Teicos Pharma Ltd. 6.22. Teva Pharmaceutical s Industries Ltd. 6.23. Vitalograph Ltd. For more information about this report visit https://www.researchandmarkets.com/r/lxjqj4 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. Media Contact: Research and …

COVID-19 Impact on Bile Duct Cancer Market, Global Research Reports 2020-2021 | 5/26/2020

… US$ Million) Global Bile Duct Cancer Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) Key market players Major competitors identified in this market include Pfizer, F. Hoffmann-La Roche, Bristol-Myers Squibb, Teva Pharmaceutical , Eli Lilly and Company, Sanofi, Fresenius Kabi, Mylan, etc. Based on the Region: Asia-Pacific (China, Japan, South Korea, India and ASEAN) North America (US and Canada) Europe (Germany, France, UK and Italy) Rest …

Follow Teva Pharmaceutical:    

COVID-19 Impact on Antihistamine Drugs Market, Global Research Reports 2020-2021 | 5/26/2020

… 2019- 2020 (quarterly data), (US$ Million) & (K Units) Key market players Major competitors identified in this market include Bayer, Almirall, Meda Consumer Healthcare, AstraZeneca, Johnson & Johnson, Novartis, Sanofi, Pfizer, Boehringer Ingelheim, Akorn, Merck & Co., Teva Pharmaceutical , etc. Based on the Region: Asia-Pacific (China, Japan, South Korea, India and ASEAN) North America (US and Canada) Europe (Germany, France, UK and Italy) Rest of World (Latin America, Middle East & Africa) Based …

COVID-19 Impact on Antidiuretic Drugs Market, Global Research Reports 2020-2021 | 5/26/2020

… K Units) Global Antidiuretic Drugs Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units) Key market players Major competitors identified in this market include Par Sterile Products, ADH Health, Azevan Pharmaceuticals, Teva Pharmaceutical , Otsuka Holdings, Taj Pharmaceuticals, ALLERGAN, etc. Based on the Region: Asia-Pacific (China, Japan, South Korea, India and ASEAN) North America (US and Canada) Europe (Germany, France, UK and Italy) Rest of World (Latin …

COVID-19 Impact on Anti Asthma Drugs Market, Global Research Reports 2020-2021 | 5/26/2020

… Global Anti Asthma Drugs Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units) Key market players Major competitors identified in this market include GlaxoSmithKline, Merck & Co, AstraZeneca, F. Hoffmann-La Roche, Teva Pharmaceutical , Novartis International, Boehringer Ingelheim, Sunovion Pharmaceuticals, etc. Based on the Region: Asia-Pacific (China, Japan, South Korea, India and ASEAN) North America (US and Canada) Europe (Germany, France, UK and Italy) Rest of World …

FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis | PR Newswire | 5/26/2020

… to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron’s agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating …

Teva Announces Virtual 2020 Annual Meeting of Shareholders | 5/26/2020

TEL AVIV, Israel–( BUSINESS WIRE )– Teva Pharmaceutical s Industries Ltd. (NYSE: TEVA, TASE: TEVA) (“Teva”), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of the current COVID-19 pandemic, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Teva’s 2020 Annual Meeting will be held on Tuesday, June 9, 2020 at 4:30 …

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine - Business Wire | 5/25/2020

TEL AVIV, Israel- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY ® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6 th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic. The fremanezumab data included pooled analyses of the AJOVY Phase 3 clinical …

Weekly Analysts’ Ratings Updates for Teva Pharmaceutical Industries (TEVA) | 5/25/2020

A number of research firms have changed their ratings and price targets for Teva Pharmaceutical Industries (NYSE: TEVA): 5/11/2020 – Teva Pharmaceutical Industries was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating. 5/11/2020 – Teva Pharmaceutical Industries had its price target raised by analysts at UBS Group AG from $12.00 to $15.00. They now have a “buy” rating on the stock. 5/8/2020 – Teva Pharmaceutical Industries had …

Sequoia Financial Advisors LLC Invests $126,000 in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) | 5/25/2020

Sequoia Financial Advisors LLC acquired a new position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 14,025 shares of the company’s stock, valued at approximately $126,000. Several other institutional investors also recently made changes to their positions in TEVA. Nwam LLC boosted its stake in Teva Pharmaceutical …

In-Depth Analysis for Cardiology Information System Market by 2020-2027 Focusing on Top Players Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG | 5/25/2020

… a comprehensive market analysis and major player’s landscape. Ask for Sample Copy of This Report: https://www.qyreports.com/request-sample/?report-id=223538 Top Key Players Included in This Report: Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, The report on the UK Cardiology Information System Market has newly added by QY Reports to its huge repository …

Germany Respiratory Devices Market 2019-2025 - ResearchAndMarkets.com | Business Wire | 5/25/2020

… T Presspart Manufacturing Ltd. 6.14. Hamilton Medical AG 6.15. Koninklijke Philips N.V. 6.16. Medtronic PLC 6.17. Novartis AG 6.18. PMD Device Solutions Ltd. 6.19. ResMed Corp. 6.20. Savara, Inc. 6.21. Teicos Pharma Ltd. 6.22. Teva Pharmaceutical s Industries Ltd. 6.23. Vitalograph Ltd. For more information about this report visit https://www.researchandmarkets.com/r/kc7cmx Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN …

Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase | PR Newswire | 5/25/2020

… to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron’s agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating …

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine | Financial Buzz | 5/25/2020

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY ® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6 th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic. The fremanezumab data included pooled analyses of the AJOVY Phase 3 clinical trials (FOCUS, HALO …

Edited Transcript of TEVA.TA earnings conference call or presentation 7-May-20 12:00pm GMT | Yahoo News | 5/24/2020

Q1 2020 Teva Pharmaceutical Industries Ltd Earnings Call Petah Tikva May 24, 2020 (Thomson StreetEvents) – Edited Transcript of Teva Pharmaceutical Industries Ltd earnings conference call or presentation Thursday, May 7, 2020 at 12:00:00pm GMT TEXT version of Transcript Corporate Participants Brendan O’Grady Teva Pharmaceutical Industries Limited - EVP of North America Commercial Eliyahu Sharon Kalif Teva Pharmaceutical Industries Limited - Executive VP & CFO Kåre Schultz Teva Pharmaceutical Industries Limited - President, CEO & Director …

Cambridge Investment Research Advisors Inc. Acquires 145,683 Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) | 5/24/2020

Cambridge Investment Research Advisors Inc. grew its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 91.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 304,822 shares of the company’s stock after acquiring an additional 145,683 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Teva Pharmaceutical Industries were …

Biosimilar Drug Market to Witness an Outstanding Growth To 2020 | Sandoz, Amgen, Teva Pharmaceutical Industries, Hospira, STADA Arzneimittel, Mylan | 5/23/2020

… factors are responsible for the market’s growth, which are studied in detail in this research report. Ask for Sample https://www.researchnreports.com/request_sample.php?id=49913 Top Key Players Profiled in This Report: Sandoz, Amgen, Teva Pharmaceutical Industries, Hospira, STADA Arzneimittel, Mylan This report covers Global Biosimilar Drug Market from the bottom line, starting from its definition. Later, it segments the market on various criteria to give a depth of understanding …

Dupixent® (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints | PR Newswire | 5/23/2020

… to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron’s agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating …

Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injection) at European Academy of Neurology Congress | Business Wire | 5/22/2020

TEL AVIV, Israel- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data on AJOVY ® (fremanezumab) and the burden of migraine in Europe will be presented at the 6 th Congress of the European Academy of Neurology (EAN), being held virtually from 23-26 May 2020. Additionally, Teva will present data on the long-term safety and efficacy of COPAXONE ® (glatiramer acetate injection). This year’s EAN congress is …

Chronic Kidney Disease Drugs Market Size, Analysis, Opportunity Assessment, Forecast 2027 | Key Players Amgen, Teva Pharmaceutical Industries Ltd, Pfizer, AstraZeneca, F. Hoffmann-La Roche, Sanofi S.A | 5/22/2020

… kidney function.” Request Sample Copy of this [email protected]: https://www.healthcareintelligencemarkets.com/request_sample.php?id=29652 This market research report on analyzes the growth prospects for the key vendors operating in this market space including Amgen, Teva Pharmaceutical Industries Ltd, Pfizer, AstraZeneca, F. Hoffmann-La Roche, Sanofi S.A, Kissei Pharmaceutical Co, AbbVie, GlaxoSmithKline, Keryx Biopharmaceuticals The increasing demand for the above-mentioned market in the well-established and emerging regions as well …

Fosun International Ltd Increases Stock Position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) | 5/22/2020

Fosun International Ltd increased its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 80.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 162,000 shares of the company’s stock after buying an additional 72,000 shares during the period. Fosun International Ltd’s holdings in Teva Pharmaceutical Industries were worth $1,379,000 as of its most recent SEC filing. A number …

Coronavirus Report: The Hill’s Steve Clemons interviews Brendan O’Grady | 5/22/2020

The Hill’s Steve Clemons interviews Brendan O’Grady By Steve Clemons - 05/20/20 06:08 PM EDT The Hill’s Steve Clemons interviews Brendan O’Grady, president and CEO of Teva Pharmaceutical s USA. Read excerpts from the interview below. Clemons: How do you look at the issue of supply chains right now? O’Grady: I think before this started nobody really cared about supply chains. Nobody even really thought much about it. But Teva is the …

Paget’s Disease Treatment Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026| | 5/22/2020

… margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation. Key companies operating in the global Paget’s Disease Treatment market include _ Novartis AG, Mylan NV, Teva Pharmaceutical Industries Ltd., Neopharma, Inc., Sanofi S.A., Allergan(AbbVie), Fresenius Kabi, Sun Pharmaceutical Industries, Ltd., Mallinckrodt Pharmaceuticals Get PDF Sample Copy of the Report to understand the structure of the complete report: ( Including Full TOC …

Chronic Obstructive Pulmonary Disease Treatment Market Size, Share, Emerging Trends, Analysis and Forecasts to 2027 | 5/22/2020

… databases). Further, the market has been estimated by utilizing various research methodologies and internal statistical model. Get sample PDF copy @ https://www.theinsightpartners.com/sample/TIPRE00008520/ The key players influencing the market are: 1. Abbott 10. Teva Pharmaceutical Industries Ltd. This report contains: Market sizing for the global Chronic Obstructive Pulmonary Disease Treatment Market. Compare major Chronic Obstructive Pulmonary Disease Treatment providers strategies and approaches to the challenges they face Analysis of …

Meitav Dash Investments Ltd. Has $2.84 Million Holdings in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) | 5/22/2020

Meitav Dash Investments Ltd. lifted its holdings in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 2,989.6% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 318,224 shares of the company’s stock after acquiring an additional 307,924 shares during the period. Meitav Dash Investments Ltd.’s holdings in Teva Pharmaceutical Industries were worth $2,842,000 as of its most recent filing with the SEC …

Consumer Healthcare

New Directors Elected to BiondVax’s Board of Directors | PR Newswire | 3/24/2020

… strategic alliances. He also led a number of businesses including as President of U.S. Pharmaceuticals and as President of Worldwide Consumer Healthcare. Mr. Moed received a BA in history from Columbia University in New York … capital firm focused on healthcare, and a program manager at Teva Pharmaceuticals. Dr. Margolin holds a BSc in biology and a MSc Cum Laude from the department of microbiology, both from Tel Aviv University in …

COVID-19

Hospital orders for old malaria drugs have spiked amid coronavirus pandemic | STAT | 3/24/2020

… demand suddenly grew thanks to several medical papers that indicated the drugs may show promise as a weapon to fight Covid-19. Although definitive evidence was lacking, the panic over the pandemic prompted a blizzard … production. In some cases, companies such as Bayer (BAYRY) and Teva Pharmaceuticals (TEVA) have agreed to donate millions of tablets. There is still no definitive evidence that either drug works – or would be effective when …

Food and Drug Administration

Coronavirus update: 284,566 cases, 11,868 deaths, New York and Illinois in lockdown - MarketWatch | 3/21/2020

… Food and Drug Administration’s compassionate use program. At least three drugmakers — Bayer AG BAYRY, -2.63% , Mylan MYL, +2.56% , and Teva Pharmaceutical Industries Ltd. TEVA, +1.39% — have upped production of chloroquine products. In the case of Mylan, it is restarting a manufacturing line altogether. That said, chloroquine has not been designated a proven COVID-19 treatment by the FDA as it has not received an approval for this indication. More than …

Genomics

Global Precision Medicine Market Review 2016-2019 and Forecast to 2026, Featuring Financials of Key Players | PR Newswire | 2/21/2020

Teva Pharmaceutical Industries, Tepnel Pharma Services, Quest Diagnostics Incorporated, Qiagen, Pfizer, Novartis, Nanostring Technologies, Medtronic, Laboratory Corporation of America Holdings, Intomics, Hoffmann-La Roche, Ferrer inCode, Eagle Genomics, and Biocrates Life Sciences. Key Questions Answered in the Report How this market evolved since the year 2016 Market size estimations, forecasts and CAGR for all the segments presented in the scope Key Market Developments and financials of the key players Opportunity …

Clinical Research

EYLEA® (aflibercept) Injection Reduced Risk of Developing Vision-Threatening Events by 75% After Two Years in Patients with Diabetic Retinopathy | PR Newswire | 2/9/2020

… from PANORAMA were previously reported in October 2018 and February 2019 . A separate ongoing trial sponsored by the Diabetic Retinopathy Clinical Research Network known as Protocol W is also evaluating EYLEA for the treatment of … or collaboration agreement, including Regeneron’s agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with …

Regenerative Medicine

Hormonal Contraceptives Market to Exhibit 5.8% CAGR by 2026, Market to Gain from Increasing Prevalence of Unwanted Pregnancies, Projects Fortune Business Insights™ | Globe Newswire | 2/5/2020

… ring used for preventing pregnancy. List of Significant Players of the Hormonal Contraceptives Market Include: Piramal Enterprises Ltd Novartis AG Teva Pharmaceutical Industries Janssen Pharmaceuticals, Inc. Allergan Merck & Co., Inc. Pfizer, Inc. Mylan N.V. Have … By End User (Healthcare Facilities, Homecare), and Regional Forecast 2019-2026 Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology …

Mental Health

Depression Drugs Market Growth, Trends, Absolute Opportunity and Value Chain 2018 2026 | 1/21/2020

… adults had experienced at least one major depressive episode that resulted in severe impairment, according to the National Institute of Mental Health (NIMH). High prevalence of such depressive episode was observed among people aged 18-25 … Inc., Alkermes Plc, H. Lundbeck, Bristol Myers Squibb Co., and Teva Pharmaceutical Industries Ltd. About Fact.MR Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market …

Medicaid

Teva Pharmaceuticals Agrees To Pay $54 Million To Settle Shepherd, Finkelman, Miller & Shah, LLP False Claims Act Qui Tam Case | PR Newswire | 1/6/2020

… SFMS”)( www.sfmslaw.com ), Lead Litigation Counsel for plaintiffs-relators, Charles Arnstein and Hossam Senousy (the “Relators” or “Whistleblowers”), announced today that Teva Pharmaceuticals (“Teva”) has agreed to settle alleged violations of the False Claims Act based … Carrie L. Bashaw , Senior Counsel of the State of Washington Medicaid Fraud Control Unit and Kathryn M. Heim Harris , Special Assistant Attorney General of the New York Medicaid Fraud Control Unit, for their persistence and …

Biotech

Rafael Holdings Launches Cancer Drug Development Initiative – Company Announcement - FT.com | Financial Times | 12/20/2019

… Teva Pharmaceuticals , Chairman of Centrexion Therapeutics , Lead Director of Contrafect Corp , Chairman of Neximmune, and Board member of 3DBioteherapeutics and Aevi Genomic Therapeutics, Founding Chair of the Hackensack Meridian Center for Discovery and Innovation and advisor to the Israel Biotech Fund . Dr. Barer is a co-founder of Celgene Corporation and served as Celgene’s Executive Chairman, President, CEO, and COO. Previously, he was the founder of the biotechnology group at …

Big Pharma

AOC Falsely Claims She Fast-Tracked HIV Drugs to Market - Washington Free Beacon | 12/4/2019

… to President Trump’s criticism of House Democrats, the progressive congresswoman fabricated a personal achievement by claiming that she “took on Big Pharma” with “colleagues in hearings that brought PrEP generic a year early” in a … the medicine. However, a 2014 legal settlement between Gilead and Teva Pharmaceutical authorized the latter to sell generic Truvada starting in 2020, a year before the patent is set to expire. In May, Gilead representative …

Medicare

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene … Foundation [UK] Broad Institute [US] Cancer Research UK Centers for Medicare and Medicaid Services (CMS) [US] Chinese State Food and Drug Administration (SFDA) Commonwealth Scientific and Industrial Research Organisation (CSIRO) [ Australia ] EMA (European Medicines Agency …

Biosimilars

Teva Pharmaceuticals Stock Is Safe With Settlement Talks Underway | 12/4/2019

Stocks to Buy / Teva Pharmaceuticals Stock Is Safe With Settlement Talks Underway Teva Pharmaceuticals Stock Is Safe With Settlement Talks Underway Despite the recent rally, TEVA stock is still inexpensive at current levels By Chris Lau 56 Teva Pharmaceuticals (NYSE: TEVA ) started attracting buyers in the last few months for good reason. The generics drug supplier is working with the government to resolve differences, and the company is showing signs …

National Institutes of Health

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… SABiosciences (now part of QIAGEN) Sandor Proteomic Sanger Institute Sanofi Santaris Pharma Servier Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene Trans-Hit Biomarkers Tufts Center for the Study of Drug Development Ventana Medical Systems Vertex Pharmaceuticals WaferGen Warnex Worldwide Clinical Trials WuXi …

NIH

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene … Aging ( NIA) [US] National Jewish Health [US] Newcastle University [UK] NIH (National Institute of Health) Oslo University Hospital Pharmaceutical Research and Manufacturers of America (PhRMA) Pharmaceuticals and Medical Devices Agency (PMDA) [ Japan ] Predictive Safety Testing …

Centers for Medicare and Medicaid Services

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene … British Heart Foundation [UK] Broad Institute [US] Cancer Research UK Centers for Medicare and Medicaid Services (CMS) [US] Chinese State Food and Drug Administration (SFDA) Commonwealth Scientific and Industrial Research Organisation (CSIRO) [ Australia ] EMA (European …

CDC

J&J’s Pay Out Amount is Reduced Due to “Math Error” | 12/4/2019

… hand, said it should receive a “$355 million credit, reflecting pre-trial settlements by the drugmakers Purdue Pharma LP and Teva Pharmaceutical Industries Ltd.” To this, Balkman responded that the state does not allow for … According to the U.S. Centers for Disease Control and Prevention (CDC), “Opioids were involved in almost 400,000 overdose deaths from 1999 to 2017.” Sources …

National Cancer Institute

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene … Planck Institute for Molecular Genetics [ Germany ] National Academy of Sciences National Cancer Institute (NCI) [US] National Health Service (NHS) [UK] National Human Genome Research Institute (NHGRI) [US] National Institute for Health and Clinical Excellence ( NICE …

Department of Health and Human Services

AOC Falsely Claims She Fast-Tracked HIV Drugs to Market - Washington Free Beacon | 12/4/2019

… but currently prohibits most competitors from making generic versions of the medicine. However, a 2014 legal settlement between Gilead and Teva Pharmaceutical authorized the latter to sell generic Truvada starting in 2020, a year before … transmission by 90 percent over the next 10 years. The Department of Health and Human Services launched a lawsuit against Gilead in early November, arguing that Gilead has infringed on Centers for Disease Control and …

Precision Medicine

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

Addiction Treatment

J&J’s Pay Out Amount is Reduced Due to “Math Error” | 12/4/2019

addiction treatment and other services needed to repair damage from the opioid epidemic over the next thirty years. Yet, given the state’s estimates, the award would only cover one year of such programs, so the measure would be largely ineffective. J&J, on the other hand, said it should receive a “$355 million credit, reflecting pre-trial settlements by the drugmakers Purdue Pharma LP and Teva Pharmaceutical Industries Ltd.” To …

Medical Research

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… J&J) KU Leuven (University of Leuven) LabCorp Life Technologies LightArray Biotech M2Gen Mayo Clinic [US] Mayo Collaborative Services MDxHealth Medical Research Council [UK] MediMedia Pharma Solutions Memorial Sloan-Kettering Cancer Center [US] Merck & Co … US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene Trans-Hit Biomarkers Tufts Center for the Study of Drug …

Precision Medicine Market

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

American Heart Association

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene Trans-Hit Biomarkers Tufts Center for the Study of Drug Development Ventana Medical Systems Vertex Pharmaceuticals WaferGen Warnex Worldwide Clinical Trials WuXi AppTec Wuxi Pharmatech Xcovery List of Organizations Mentioned in the Report American College of Cardiology Foundation (ACCF) American Heart Association (AHA) Association for Molecular Pathology (AMP) [US] British Heart Foundation [UK] Broad Institute …

Cancer Diagnostics

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… SABiosciences (now part of QIAGEN) Sandor Proteomic Sanger Institute Sanofi Santaris Pharma Servier Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene Trans-Hit Biomarkers Tufts Center for the Study of Drug Development Ventana Medical Systems Vertex Pharmaceuticals WaferGen Warnex Worldwide Clinical Trials WuXi …

Center for Devices and Radiological Health

Global Chronic Disease Management Markets to 2024, Featuring Profiles of Leading Players Roche, AbbVie, Johnson & Johnson, Bristol-Myers Squibb, Merck, GlaxoSmithKline, and More | The Wapakoneta Daily News | 12/3/2019

Teva Pharmaceutical Industries Towerview Health, Inc. Translate Bio Tyme Technologies UCB Unilife Corp. Vertex Pharmaceutical Vaica Vital Connect West Pharmaceutical Services Inc. Winmedical Srl Ybrain Ypsomed Holding Ag Zogenix Inc. Zydus Cadila Chapter 14 Appendix A: List of Acronyms Chapter 15 Appendix B: Professional Organizations American Heart Association Center for Drug Evaluation and Research (CDER) Center for Devices and Radiological Health (CDRH) Centers for Medicare and Medicaid Services (CMS) European …

Novartis

Novartis Terminates Sale of Sandoz Dermatology Business - April 2, 2020 - Zacks.com | 4/2/2020

Novartis AG ( NVS - Free Report ) announced that it will not sell Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA Inc. Notably, Novartis had agreed to sell selected portions of the Sandoz … infected patients. Many other companies have also jumped the bandwagon. Teva Pharmaceutical Industries Ltd. ( TEVA - Free Report ) also announced the immediate donation of more than 6 million doses of hydroxychloroquine sulfate tablets through wholesalers to …

Merck

The Global Acute Kidney Injury Treatment Market is expected to grow from USD 1,142.12 Million in 2018 to USD 1,941.12 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.87% | Globe Newswire | 4/1/2020

Merck & Co., Inc., Novartis International AG, and Teva Pharmaceutical Industries Ltd.. On the basis of Type, the Global Acute Kidney Injury Treatment Market is studied across Intrinsic Renal Acute Kidney Injury, Postrenal Acute Kidney Injury, and Prerenal Acute Kidney Injury.On the basis of Treatment, the Global Acute Kidney Injury Treatment Market is studied across Dialysis and Supportive Care.On the basis of End-User, the Global Acute Kidney Injury Treatment Market …

Pfizer

Drugs needed to put patients on ventilators in short supply | Becker’s Hospital Review | 4/1/2020

Pfizer reported manufacturing delays and Teva Pharmaceuticals stopped making one of the anesthetic drugs in demand last year. Drugmakers also may not be increasing production in response to the increased demand, Erin Fox, PharmD, who tracks drug shortages for University of Utah Health, told Stat . “Everyone has been focused on possible shortages due to China halting production or India halting imports, but nobody is talking about shortages due to a …

Boehringer Ingelheim

The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7% | Globe Newswire | 3/30/2020

Boehringer Ingelheim (Germany), Merck KgaA, Mylan (US), Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddy’s Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany). Research Coverage: The report analyzes the biosimilars market by product …

Biogen

The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7% | Globe Newswire | 3/30/2020

Biogen (US), Fresenius Kabi AG (Germany), Boehringer Ingelheim (Germany), Merck KgaA, Mylan (US), Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddy’s Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany). Research Coverage: The report …

Amgen

The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7% | Globe Newswire | 3/30/2020

Teva Pharmaceutical (Israel), Dr. Reddy’s Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany). Research Coverage: The report analyzes the biosimilars market by product, type of manufacturing, indication, and region.Apart from comprehensive geographic product …

Eli Lilly

The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7% | Globe Newswire | 3/30/2020

Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddy’s Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany). Research Coverage: The report analyzes the biosimilars market by product, type of manufacturing, indication, and region.Apart from …

Celltrion

The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7% | Globe Newswire | 3/30/2020

Teva Pharmaceutical (Israel), Dr. Reddy’s Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany). Research Coverage: The report analyzes the biosimilars market by product, type of manufacturing, indication, and region.Apart from comprehensive geographic product …

Gilead

Coronavirus Drugs Already in the Pipeline | Yahoo News | 3/25/2020

… chloroquine family) or flu drugs (favipiravir) The antimalarials are in short supply, but production is ramping up. Mylan ( MYL ) and Teva Pharmaceuticals ( TEVA ) plan to jump-start production of hydroxychloroquine, which is also approved for … something” approach, to the point that demand led its manufacturer, Gilead ( GILD ), to limit its used to clinical trials. Six large studies are ongoing. The first should report results on April 3, the second in …

Allergan

The top 10 drugs losing U.S. exclusivity in 2020 | FiercePharma | 3/17/2020

… top the list. The drug pulled in $2.6 billion in the U.S. last year, and under a patent deal with Teva Pharmaceuticals, it’ll face new generics in September. Meanwhile, Gilead is locked in a dispute … list totals some $8 billion in 2019 U.S. sales. Meanwhile, Allergan’s Restasis is one drug that just keeps dodging U.S. competition⁠—even after its patents expired⁠—thanks to regulatory struggles for generics companies. Teva has …

AbbVie

The top 10 drugs losing U.S. exclusivity in 2020 | FiercePharma | 3/17/2020

… top the list. The drug pulled in $2.6 billion in the U.S. last year, and under a patent deal with Teva Pharmaceuticals, it’ll face new generics in September. Meanwhile, Gilead is locked in a dispute … many in the industry are tracking the 2023 downfall of AbbVie’s Humira protection. The drug is so important to AbbVie that the drugmaker inked a massive buyout in Allergan to help prepare for that patent …

Bristol-Myers Squibb

The top 10 drugs losing U.S. exclusivity in 2020 | FiercePharma | 3/17/2020

… Teva Pharmaceuticals, it’ll face new generics in September. Meanwhile, Gilead is locked in a dispute with the U.S. government on HIV prevention patents on the medicine. Aside from Truvada, 2020’s top U.S. losses of exclusivity include medications from Novartis, Bristol-Myers Squibb, Merck, Eli Lilly and others. They’re drugs already facing new generics under year-end 2019 launches, plus those expected to lose exclusivity later in the year. The …

Novo Nordisk

Teva pads beyond-the-pill lineup with latest smart inhaler approval | FiercePharma | 3/11/2020

Make that three smart inhalers for Teva Pharmaceutical. Teva’s recently approved ArmonAir Digihaler monotherapy maintenance treatment rounds out its lineup of Digihaler products. The two previous Teva approvals are the Pro-Air Digihaler for rescue … Novartis has since left that partnership). In the diabetes space, Novo Nordisk, Abbott and Eli Lilly are all on track to introduce smart insulin pens that collect and share data from injection devices with patients …

AmerisourceBergen

Closely Watched Opioid Trial in New York Postponed Due to Coronavirus | U.S. News & World Report | 3/10/2020

Teva Pharmaceutical Industries Ltd. The October trial also helped push drug distributors McKesson, Cardinal Health Inc and AmerisourceBergen Corp and drugmakers Teva and J&J to propose settling all of the cases against them for $48 billion, although they have struggled to secure support for the deal. More than 3,000 lawsuits, which have mostly been brought by state and local governments, are pending against drug companies over the opioid crisis …

Qiagen

Global Precision Medicine Market Review 2016-2019 and Forecast to 2026, Featuring Financials of Key Players | PR Newswire | 2/21/2020

Teva Pharmaceutical Industries, Tepnel Pharma Services, Quest Diagnostics Incorporated, Qiagen, Pfizer, Novartis, Nanostring Technologies, Medtronic, Laboratory Corporation of America Holdings, Intomics, Hoffmann-La Roche, Ferrer inCode, Eagle Genomics, and Biocrates Life Sciences. Key Questions Answered in the Report How this market evolved since the year 2016 Market size estimations, forecasts and CAGR for all the segments presented in the scope Key Market Developments and financials of the key players Opportunity …

Medtronic

Global Precision Medicine Market Review 2016-2019 and Forecast to 2026, Featuring Financials of Key Players | PR Newswire | 2/21/2020

Teva Pharmaceutical Industries, Tepnel Pharma Services, Quest Diagnostics Incorporated, Qiagen, Pfizer, Novartis, Nanostring Technologies, Medtronic, Laboratory Corporation of America Holdings, Intomics, Hoffmann-La Roche, Ferrer inCode, Eagle Genomics, and Biocrates Life Sciences. Key Questions Answered in the Report How this market evolved since the year 2016 Market size estimations, forecasts and CAGR for all the segments presented in the scope Key Market Developments and financials of the key players Opportunity …

Quest Diagnostics

Global Precision Medicine Market Review 2016-2019 and Forecast to 2026, Featuring Financials of Key Players | PR Newswire | 2/21/2020

Teva Pharmaceutical Industries, Tepnel Pharma Services, Quest Diagnostics Incorporated, Qiagen, Pfizer, Novartis, Nanostring Technologies, Medtronic, Laboratory Corporation of America Holdings, Intomics, Hoffmann-La Roche, Ferrer inCode, Eagle Genomics, and Biocrates Life Sciences. Key Questions Answered in the Report How this market evolved since the year 2016 Market size estimations, forecasts and CAGR for all the segments presented in the scope Key Market Developments and financials of the key players Opportunity …

Johnson & Johnson

U.S. states reject $18 billion proposal to settle opioid lawsuits, discussions ongoing - sources | Yahoo News | 2/15/2020

Teva Pharmaceutical Industries TEVA.TA . A trial is scheduled to begin on March 20 in which the state of New York and the counties of Suffolk and Nassau are suing drug distributors, drugmakers such as Johnson & Johnson JNJ.J and pharmacy chains including CVS Health Corp CVS.N . The $18 billion settlement was proposed on the eve of the last major opioid trial in Cleveland in October. The New York trial date could …

GlaxoSmithKline

West Nile Virus Therapeutics Market 2019-2023 | Availability of Over-the Counter (OTC) Therapeutics to Boost Growth | Technavio | Business Wire | 2/14/2020

GlaxoSmithKline Plc, Granules India Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc. and Teva Pharmaceutical Industries Ltd. Backed with competitive intelligence and benchmarking, our research reports on the west Nile virus therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support. Register for a free trial today and gain instant access to 17,000 …

Bristol-Myers

Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation | BMJ | 2/13/2020

Teva Pharmaceutical Industries, St. Jude Medical, Janssen Research & Development, Baxter Healthcare Corporation and Cardiovascular Research Foundation. Consultant/Advisory Board for Janssen Scientific Affairs, Cipla Limited, Armetheon Inc and Medtronic. EMH: Consultant: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo, Johnson & Johnson; Research Grant from Bristol-Myers Squibb/Pfizer, Johnson & Johnson. MDE: Consultant/Advisory Board for Boehringer Ingelheim, Daiichi-Sankyo, Pfizer, Bristol-Myers Squibb and Janssen Scientific Affairs. PRK: Consultant …

UnitedHealth

Stocks close higher as worries about coronavirus wane | MSN | 2/12/2020

… global economy. “ The Dow closed 275 points higher, while the S&P 500 gained 0.65% and the Nasdaq jumped 0.9%. UnitedHealth climbed more than 4% to lead the Dow higher. Nike, Apple and Caterpillar all … in 2020. Lyft shares slid 6.9%. CVS Health, Molson Coors, Teva Pharmaceutical and Shopify all reported quarterly results that beat analyst expectations. About 70% of S&P 500 companies have posted calendar fourth-quarter results …

CVS Health

Stocks making the biggest moves in the premarket: CVS Health, Molson Coors, Moody’s & more | CNBC | 2/12/2020

… Wall Street set for higher open Morning Report Take a look at some of the biggest movers in the premarket: CVS Health (CVS) – The drug store operator beat estimates by 5 cents a share , with … what Molson Coors calls “significant headwinds and continued volume declines.” Teva Pharmaceutical (TEVA) – The world’s largest generic drugmaker beat estimates by a penny a share, with quarterly profit of 62 cents per share. Revenue also …

CVS

Stocks making the biggest moves in the premarket: CVS Health, Molson Coors, Moody’s & more | CNBC | 2/12/2020

… Wall Street set for higher open Morning Report Take a look at some of the biggest movers in the premarket: CVS Health (CVS) – The drug store operator beat estimates by 5 cents a share , with … what Molson Coors calls “significant headwinds and continued volume declines.” Teva Pharmaceutical (TEVA) – The world’s largest generic drugmaker beat estimates by a penny a share, with quarterly profit of 62 cents per share. Revenue also …

Lyft Health

Stocks making the biggest moves in the premarket: CVS Health, Molson Coors, Moody’s & more | CNBC | 2/12/2020

… share consensus estimate. Revenue also beat Wall Street projections, despite what Molson Coors calls “significant headwinds and continued volume declines.” Teva Pharmaceutical (TEVA) – The world’s largest generic drugmaker beat estimates by a penny a share … 2.26-$2.38, below the consensus estimate of $2.79 a share. Lyft (LYFT) – Lyft lost $1.19 per share for the fourth quarter, 20 cents a share less than Wall Street had been expecting. The ride-hailing …

Express Scripts

U.S. District Court for the Southern District of Illinois: Actions Taken on Jan. 30 | 2/7/2020

Express Scripts Holding Company , Express Scripts, Inc. , H J Harkins Co., Inc. , Hetero Drugs, Limited , Hetero Labs, Ltd. , Hetero USA Inc. , Huahai US Inc. , Major Pharmaceuticals, Inc. , Medicine Shoppe International, Inc. , Mylan Laboratories, Ltd. , Mylan N. V. , Mylan Pharmaceuticals, Inc. , Northwind Pharmaceuticals , NuCare Pharmaceuticals, Inc. , Praxis Specialty Pharmacy, LLC , Preferred Pharmaceuticals, Inc. , Remedy Repack, Inc. , Rite Aid Corporation , Solco Healthcare US, LLC , Teva Pharmaceutical Industries, Ltd. , Teva Pharmaceuticals USA, Inc …

Zacks Investment Research

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Expected to Announce Earnings of $0.62 Per Share | Daily Political | 2/7/2020

Wall Street brokerages expect Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to report earnings per share of $0.62 for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Teva Pharmaceutical Industries’ earnings. The … Pharmaceutical Industries (TEVA) For more information about research offerings from Zacks Investment Research, visit Zacks.com …

Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know | Zacks | 2/6/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Teva Pharmaceutical Industries Ltd. ( TEVA - Free Report ) closed at $12.10 in the latest trading session, marking a +0.33% move from the prior day. This change lagged the S&P 500’s 1.13% gain on the day. At the same time, the Dow …

Wedbush Securities

Zurcher Kantonalbank Zurich Cantonalbank Has $2.54 Million Holdings in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) | 1/28/2020

Zurcher Kantonalbank Zurich Cantonalbank lessened its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 20.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 259,535 shares of the company’s stock after selling … 45,000 after buying an additional 1,294 shares during the period. Wedbush Securities Inc. grew its position in shares of Teva Pharmaceutical Industries by 17.2% during the 4th quarter. Wedbush Securities Inc. now owns 49,639 shares …

Carlyle Group

Barer Institute Announces Founding Board Members | PR Newswire | 1/14/2020

… provide strategic direction to the Institute’s development and collaboration efforts.” Sol J. Barer , Ph.D., is Chairman of the Board of Teva Pharmaceuticals, Chairman of Centrexion Therapeutics, Lead Director of Contrafect Corp, Chairman of Neximmune, Board … the American Stock Exchange and a senior advisor to the Carlyle Group. Mr. Levitt is currently a member of the board of Bloomberg LP, and a Senior Advisor to the Promontory Financial Group, an IMB …

Biogen Idec

Multiple Sclerosis Therapeutics Market To Reach USD 25.91 Billion By 2026 | Reports And Data | Globe Newswire | 12/4/2019

… Biogen Idec, Teva Pharmaceuticals, Bayer Healthcare, Pfizer, Sanofi-Aventis, Merck, and Novartis, AbbVie Inc., Acorda Therapeutics Inc. To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/multiple-sclerosis-therapeutics-market Segments covered in the report: For the purpose of this report, Reports and Data has segmented the Multiple Sclerosis Therapeutics market on the basis of product type, mode of administration type, distribution …

SunTrust Bank

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) VP Hafrun Fridriksdottir Sells 4,310 Shares - WKRB News | 12/3/2019

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) VP Hafrun Fridriksdottir sold 4,310 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.49, $45,211.90. Following the … TEVA has been the subject of several research analyst reports. SunTrust Banks lowered their price objective on Teva Pharmaceutical Industries to $7.00 and set a “hold” rating for the company in a report on Thursday …

Morgan Stanley

General Electric (NYSE:GE) Receiving Very Critical Press Coverage, Report Finds - TheOlympiaReport | 11/28/2019

… for Technicians Fuels National Aviation Academy Career Fair (prweb.com) Thinking about buying stock in Apple, General Electric, Macy’s, Nio, or Teva Pharmaceutical? (prnewswire.com) General Electric Appoints a New CFO as It Looks to Boost Results … buy” rating in a research note on Wednesday, September 4th. Morgan Stanley began coverage on General Electric in a research note on Thursday, September 5th. They issued an “equal weight” rating and a $10.00 target …

Citigroup

General Electric (NYSE:GE) Receiving Very Critical Press Coverage, Report Finds - TheOlympiaReport | 11/28/2019

… Teva Pharmaceutical? (prnewswire.com) General Electric Appoints a New CFO as It Looks to Boost Results, GE Stock (feedproxy.google.com) Three Cheers For General Electric: Outsider For New CFO (seekingalpha.com) Maersk executive new General Electric CFO (timesunion.com) Several research firms have issued reports on GE. William Blair reiterated a “buy” rating on shares of General Electric in a research note on Friday, August 16th. Citigroup set a $14.00 target price on General …

William Blair

General Electric (NYSE:GE) Receiving Very Critical Press Coverage, Report Finds - TheOlympiaReport | 11/28/2019

… Teva Pharmaceutical? (prnewswire.com) General Electric Appoints a New CFO as It Looks to Boost Results, GE Stock (feedproxy.google.com) Three Cheers For General Electric: Outsider For New CFO (seekingalpha.com) Maersk executive new General Electric CFO (timesunion.com) Several research firms have issued reports on GE. William Blair reiterated a “buy” rating on shares of General Electric in a research note on Friday, August 16th. Citigroup set a $14.00 target price on General …

Goldman Sachs

First Edition: November 27, 2019 | Kaiser Health News | 11/27/2019

… received subpoenas from the U.S. Attorney’s office in the Eastern District of New York as part of the investigation: drugmakers Teva Pharmaceutical Industries Ltd, Mallinckrodt Plc, Johnson & Johnson and Amneal Pharmaceuticals Inc, and distributor McKesson … portraying itself as a success to its investors, which included Goldman Sachs, Google-affiliated CapitalG, and the Pritzker Group. (Herper, 11/26) The New York Times: Fertility Rate In U.S. Hit A Record Low In 2018 …

Blackstone Group

Reuters Health News Summary | Yahoo News | 11/26/2019

… least six companies have received grand-jury subpoenas from the U.S. attorney’s office in the Eastern District of New York - Teva Pharmaceutical Industries Ltd, Mallinckrodt Plc , Johnson & Johnson and Amneal Pharmaceuticals Inc and distributors AmerisourceBergen … to invest $400 million in gene therapy venture with Ferring Blackstone Group Inc said on Monday it will invest $400 million in a joint venture with Swiss drug company Ferring that is working on an …

JP Morgan

36 Healthcare Stocks Moving In Monday’s Pre-Market Session | Benzinga | 11/25/2019

Teva Pharmaceutical Indus, Inc. (NYSE: TEVA ) stock surged 2.7% to $10.50. The market value of their outstanding shares is at $8.9 billion. According to the most recent rating by JP Morgan, on November 12, the current rating is at Neutral. CRISPR Therapeutics, Inc. (NASDAQ: CRSP ) stock surged 2.6% to $63.85. The market cap stands at $2.7 billion. The most recent rating by Oppenheimer, on November 12, is at Outperform, with …

Maxim Group

36 Healthcare Stocks Moving In Monday’s Pre-Market Session | Benzinga | 11/25/2019

… Maxim Group, on September 06, is at Buy, with a price target of $2.00. Teva Pharmaceutical Indus, Inc. (NYSE: TEVA ) stock surged 2.7% to $10.50. The market value of their outstanding shares is at $8.9 billion. According to the most recent rating by JP Morgan, on November 12, the current rating is at Neutral. CRISPR Therapeutics, Inc. (NASDAQ: CRSP ) stock surged 2.6% to $63.85. The market cap stands at $2.7 …

Redmile Group

Global Myelodysplastic Syndrome Treatment Market to Surpass US$ 4,994.7 million by 2027 - Coherent Market Insights | Business Wire | 11/25/2019

… in November 2018, Aprea Therapeutics announced completion of US$ 56 million series C financing round led by healthcare investment organization, Redmile Group, along with participation of new investor Rock Springs Capital and current existing investors … syndrome treatment market include - Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics …

SVB Leerink

Shares of generic drugmakers rise on hope that legal issues are nearing an end - MarketWatch | 11/25/2019

… mounted about a series of legal settlements potentially nearing a resolution. Mallinckrodt’s MNK, +11.42% stock rallied 15%, while shares of Teva Pharmaceutical Industries Ltd. TEVA, +4.79% rose 5%. Mylan MYL, +4.15% and Endo International ENDP … opioid liability,” SunTrust Robinson Humphrey’s Gregg Gilbert wrote Nov. 11. SVB Leerink analysts predict the global settlement will be reached within the next four months. “We could also see read-through for other opioid-levered …

RBC Capital Markets

Teva spin-off 89bio soars after $85m Nasdaq IPO | 11/17/2019

RBC Capital Markets acted as joint book-running managers for the offering and Oppenheimer & Co. acted as co-manager. The company had planned to raise $70 million until last week but then decioded to upsize the IPO. 89bio is in effect a spin-off of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA ; TASE: TEVA ). Teva inherited what is now bio89’s lead product candidate, BIO89-100 for the treatment of nonalcoholic steatohepatitis …

Merrill Lynch

Teva Pharmaceutical Industries Limited (TEVA) CEO Kare Schultz on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/7/2019

Teva Pharmaceutical Industries Limited (NYSE: TEVA ) Q3 2019 Results Conference Call November 7, 2019 8:00 AM ET Company Participants Kevin Mannix - Senior Vice President of Investor Relations Kare Schultz - President and Chief Executive Officer Michael … JPMorgan Akash Tewari - Wolfe Research Jason Gerberry - Bank of America Merrill Lynch David Amsellem - Piper Jaffray Umer Raffat - Evercore ISI Gary Nachman - BMO Capital Markets Operator Ladies and gentlemen, thank you for standing by, and …

Daiichi Sankyo

Global HIV Drugs Market Report 2019-2025: Market is Projected to Grow $6.3 Billion | PR Newswire | 11/6/2019

Daiichi Sankyo Co., Ltd. Emcure Pharmaceuticals Pvt., Ltd. F. Hoffmann-La Roche AG Gilead Sciences, Inc. Hetero Drugs Ltd. Johnson & Johnson Merck & Co., Inc. Teva Pharmaceutical Industries Ltd. ViiV Healthcare Key Topics Covered: 1. Market Overview 2. Focus On Select Players 3. Market Trends & Drivers 4. Global Market Perspective For more information about this report visit https://www.researchandmarkets.com/r/elvw7v Research and Markets also offers Custom Research services providing focused …

Bain Capital

Cerevel Therapeutics adds to board | PE Hub | 11/4/2019

… chairperson of Whole Foods ‘ board and currently serves as general partner of Rustic Canyon/Fontis Partners . Cerevel is backed by Bain Capital . PRESS RELEASE BOSTON–(BUSINESS WIRE)–Cerevel Therapeutics, a company dedicated to unraveling the … Sulzberger has also served on four other public company boards: Teva Pharmaceuticals, Stage Stores, IndyMac Bank, and Bright Horizons, as well as numerous private company boards. Ms. Sulzberger is a Trustee of the Ford Foundation …

Rustic Canyon/Fontis Partners

Cerevel Therapeutics adds to board | PE Hub | 11/4/2019

… its board of directors. She is a former chairperson of Whole Foods ‘ board and currently serves as general partner of Rustic Canyon/Fontis Partners . Cerevel is backed by Bain Capital . PRESS RELEASE BOSTON–(BUSINESS WIRE … Sulzberger has also served on four other public company boards: Teva Pharmaceuticals, Stage Stores, IndyMac Bank, and Bright Horizons, as well as numerous private company boards. Ms. Sulzberger is a Trustee of the Ford Foundation …

Advent International

Global Cell Encapsulation Research Report 2019-2030 | PR Newswire | 10/30/2019

… Cancer League Swiss Group for Clinical Cancer Research Sylvatica Biotech SymbioCellTech Symbiose Biomaterials Tactiva Therapeutics Taiwan Bio Therapeutics Takara Bio Takeda Pharmaceutical Targazyme TC BioPharm TCR2 Therapeutics Technocampus Group Tella Terumo Tessa Therapeutics Teva Pharmaceutical TheraCyte Thermo Fisher Scientific Thomas Jefferson University Tianhe Stem Cell Biotechnologies Tianjin Ever Union Biotechnology TiGenix TILT Biotherapeutics Tmunity Therapeutics TNK Therapeutics TotipotentRX TPG Capital TRACT Therapeutics TransCure BioServices Translational Drug Development Trinity College Dublin …

Macquarie

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Position Decreased by Cacti Asset Management LLC | 10/10/2019

Cacti Asset Management LLC lessened its holdings in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 97.1% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned … other hedge funds have also modified their holdings of TEVA. Macquarie Group Ltd. increased its position in Teva Pharmaceutical Industries by 35.9% during the second quarter. Macquarie Group Ltd. now owns 2,006,900 shares of the …

NCI

North America accounted for the largest share, accounting for approximately 30% of the global market, in 2017 | PR Newswire | 9/4/2019

… coming decade, there would be a rise in the patent expiration of several existing biological drugs, such as Erbitux, Avastin, Orencia, and others, which would provide an opportunity for many innovator companies as well as … presence of many large research laboratories, such as Sandoz, Amgen, Teva Pharmaceutical, and others. According to a recent report, more than 40 biosimilars are under development, including approximately 20 biosimilars ready to be released into …

U.S. Bancorp

Warren Buffett’s portfolio yields a big surprise | MSN | 8/20/2019

… in the finance space, with Buffett and/or his team adding to Berkshire’s existing positions in Bank of America and U.S. Bancorp. Berkshire has held stock in U.S. Bancorp for 13 years and counting. The … do a thing with two of the biggest portfolio drags: Teva Pharmaceutical Industries and Kraft Heinz. Teva Pharmaceutical, which was first added to the Berkshire Hathaway portfolio – by someone other than Buffett – during the fourth …

Abrams Capital

Tracking David Abrams’ Abrams Capital Management Portfolio - Q2 2019 Update | Seeking Alpha | 8/11/2019

… a quarterly basis. It is based on Abrams’ regulatory 13F Form filed on 08/09/2019. Please visit our Tracking David Abrams’ Abrams Capital Management article for an idea on his investment philosophy and our last update … 14.75 and $19.75 and the stock is currently at $20.37. Teva Pharmaceutical ( TEVA ): TEVA is currently a 4.52% of the portfolio stake. It was established in Q3 2017 at prices between $15.50 and $33.50. The …

Mayo Clinic

40 GI company developments in 2019 | Becker’s ASC Review | 12/23/2019

… a globally focused cancer diagnostics company in the process. Bausch Health subsidiary Salix Pharmaceuticals settled an intellectual property case against Teva Pharmaceuticals over Salix’s ulcerative colitis drug Apriso. Artificial intelligence device-maker NinePoint Medical received … facility in Rochester, Minn., through a partnership with Rochester-based Mayo Clinic. Gastroenterology-focused pharmaceutical company Phantom Pharmaceuticals appointed Terrie Curran as CEO after Celgene Corp. was acquired by Bristol-Myers Squibb in November. The …

Massachusetts General Hospital

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene … Consortium (ICGC) Les entreprises du médicament (LEEM) [ France ] Malmö University Massachusetts General Hospital Max Planck Institute for Molecular Genetics [ Germany ] National Academy of Sciences National Cancer Institute (NCI) [US] National Health Service (NHS) [UK] National …

Memorial Sloan Kettering Cancer Center

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… SABiosciences (now part of QIAGEN) Sandor Proteomic Sanger Institute Sanofi Santaris Pharma Servier Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene Trans-Hit Biomarkers Tufts Center for the Study of Drug Development Ventana Medical Systems Vertex Pharmaceuticals WaferGen Warnex Worldwide Clinical Trials WuXi …

MD Anderson Cancer Center

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Corporation of America Laccure Lake Consumer Products Lee’s Pharmaceutical LFB Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina … Pharmaceutical SynteractHCR Takeda Pharmaceutical Tec-Pharma Telenatal Tesaro Tessa Therapeutics Teva Pharmaceutical Industries Teva Pharmaceuticals USA Theramex TherapeuticsMD Thermo Fisher Scientific Transgene Trimel Pharmaceuticals Trivector Biomed Trophogen twoXAR Unified Women’s Clinical Research University College Dublin …

Harvard Medical School

Tuesday, November 26, 2019 | Kaiser Health News | 11/26/2019

… sell its medicine without lower-cost competition. (Silverman, 11/25) Bloomberg: Teva, Drugmakers In Talks With U.S. To End Generics Probes Teva Pharmaceutical Industries Ltd. and other generic drugmakers have held talks with the U.S. Justice … Unapproved Drug New research led by Dr. Pieter Cohen of Harvard Medical School documents five supplement brands for sale in the U.S. that contain various amounts of piracetam, a drug prescribed in European countries for …

Cleveland Clinic

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia | BMJ | 11/15/2019

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia Hubert H Fernandez 1 , William G Ondo 7 , 8 , L Fredrik Jarskog 9 , David R Shprecher 13 , 14 , Karen E Anderson 15 1 Center for Neurological Restoration , Cleveland Clinic Foundation , Cleveland , Ohio , USA 2 Former employee of Teva Pharmaceuticals , La Jolla , California , USA 3 Teva Pharmaceuticals , Frazer , Pennsylvania , USA 4 Jean and Paul Amos Parkinson’s Disease and …

HCA

Nov 06, 2019 - Beck Mack & Oliver Llc Buys Blackstone Group Inc, Jefferies Financial Group Inc, Charles Schwab Corp, Sells Blackstone Group Inc, HomeFed Corp, iShares MSCI EAFE ETF - GuruFocus.com | 11/6/2019

… Mack & Oliver Llc ( Current Portfolio ) buys Blackstone Group Inc, Jefferies Financial Group Inc, Charles Schwab Corp, Advanced Drainage Systems Inc, Teva Pharmaceutical Industries, sells Blackstone Group Inc, HomeFed Corp, iShares MSCI EAFE ETF, Devon Energy … BBN1 , HOFD , APC , BDX , DD , MSI , NOV , CBS.A , QRTEA , BIP , HCA , OAK , PBT , Warning! GuruFocus has detected 9 Warning Signs with JEF. Click here to check it out. JEF 30-Year Financial Data The intrinsic …

Memorial Sloan Kettering

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML | 10/31/2019

… fees for serving on a speakers’ bureau, and fees for serving on an advisory board from Janssen, Novartis, Pfizer, and Teva Pharmaceutical Industries, and grant support and fees for serving on an advisory board from … Center, Houston (J.E.C.); Universitätsklinikum Giessen und Marburg, Marburg, Germany (A.N.); Memorial Sloan Kettering Cancer Center, New York (E. Berman); Hospital Universitari i Politècnic La Fe, Valencia, and Centro de Investigación Biomédica en Red Cáncer (CIBERONC …

AHN

TEVA 24 Hour Deadline Alert: Approximately 24 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Limited - TEVA | Globe Newswire | 8/21/2019

August 19, 2019 22:50 ET Source: Kahn Swick & Foti, LLC NEW ORLEANS, Aug. 19, Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until August 20, 2019 to file lead plaintiff applications in a securities class action lawsuit against Teva Pharmaceutical Industries Limited (NYSE: TEVA). Investor losses must relate to purchases …

McLean Hospital

Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach | Markets Insider | Business Insider | 6/24/2019

… that merged into Aldeyra, Inc. (NASDAQ: ALDX) in early 2019. Mr. von Rickenbach serves on the Board of Trustees of McLean Hospital and on the Board of Directors of NEHI (Network for Excellence in Health … officer and treasurer of Barr Pharmaceuticals, LLC, a subsidiary of Teva Pharmaceutical and the successor entity to Barr Pharmaceuticals, Inc., which was acquired by Teva in December 2008. Mr. McKee was also executive vice president …

Staten Island University Hospital

Men near the Viagra plant may be excited, but it’s not because of ‘love fumes,’ Pfizer says | 12/12/2017

… Teva Pharmaceuticals can start selling its version then, but isn’t disclosing the price. Many more generics go on sale next summer, which will steadily slash the price of generics, possibly by 90 percent. “Patients are paying fortunes. When generic Viagra comes out, they will be very happy,” said Nachum Katlowitz, a urologist at New York’s Staten Island University Hospital. The Associated Press contributed to this report …

Staten Island University Hospital, Staten Island NY

Viagra goes generic: Pfizer to launch own little white pill | CNBC | 12/7/2017

Teva Pharmaceuticals can start selling its version then, but isn’t disclosing the price. Many more generics go on sale next summer, which will steadily slash the price of generics, possibly by 90 percent. “Patients are paying fortunes. When generic Viagra comes out, they will be very happy,” said Dr. Nachum Katlowitz, a urologist at New York’s Staten Island University Hospital. Launched in 1998, Viagra was the first pill for impotence …

Northwestern Memorial Hospital

Viagra goes generic: Pfizer to launch own little white pill | CNBC | 12/7/2017

… white pill at half the $65-a-pill retail price on Monday, when its patent-protected monopoly ends. Generic maker Teva Pharmaceuticals can start selling its version then, but isn’t disclosing the price. Many more … counterfeits, from the internet. Dr. Matthias Hofer, a urologist at Northwestern Memorial Hospital in Chicago, said some of his insured patients who take Viagra wouldn’t want a generic. “They will be ecstatic if they can …

Thomas Jefferson University Hospital

The New England Journal of Medicine Publishes Data from Pivotal Phase III Trial of Fremanezumab for the Preventive Treatment of Chronic Migraine | Business Wire | 11/30/2017

JERUSALEM- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the publication of data from the pivotal Phase III HALO study evaluating the efficacy, safety and tolerability of two subcutaneous dose regimens of fremanezumab … of Neurology and Director of the Jefferson Headache Center at Thomas Jefferson University Hospital and lead author of this publication. “Results from the Phase III study of fremanezumab for the preventive treatment of chronic migraine …

Mercy Hospital, St. Louis MO

New, long-acting drugs cut frequency of migraine headaches | Chron | 11/30/2017

… half. “I very definitely benefited,” said Anne Vickers, who got the lower dose through one of the study leaders at Mercy Hospital St. Louis in Missouri. “I can have anywhere from 15 to 18 headaches … second study tested fremanezumab (frem-uh-NEZZ-yoo-mab), from Teva Pharmaceutical, for chronic migraine, defined as headaches on 15 or more days per month, at least eight of them migraines. About 1,000 patients were …

Community Health Systems

25 Stocks Moving In Thursday’s Pre-Market Session | Morningstar | 11/2/2017

Community Health Systems (NYSE: CYH ) fell 15.3 percent to $4.61 in pre-market trading following larger-than-expected Q3 loss. OraSure Technologies, Inc. (NASDAQ: OSUR ) fell 13.3 percent to $16.50 in pre-market trading. OraSure posted Q3 earnings of $0.09 per share on revenue of $42.3 million. Wayfair Inc (NYSE: W ) shares fell 12.6 percent to $65.02 in pre-market trading after reporting downbeat Q3 results. **Teva Pharmaceutical **Industries Ltd …

University Pediatric Hospital, San Juan PR

76-Ton Airlift of Medicine and Medical Supplies Lands in Puerto Rico | PR Newswire | 10/28/2017

… island treating patients with diabetes. (Gordon Willcock/Direct Relief photo) Hemophilia treatment medicines are transported into the emergency room at University Pediatric Hospital in San Juan, Puerto Rico, on Oct. 4 The hospital was hours … Pharmaceuticals, Inc.; Sanofi Foundation for NA; Sappo Hill Soapworks; Starbucks; Teva Pharmaceuticals, USA ; Trividia Health; Vaseline; Wisconsin Pharmacal Company. Responding to an Unprecedented Hurricane Season Today’s airlift follows several weeks of smaller-scale airlifts and …

Partners HealthCare

Partners Connected Health Names A Team From McLean Hospital Winner Of The 2017 Connected Health Innovation Challenge (CHIC) | PR Newswire | 10/26/2017

… Innovation Challenge (CHIC). The Challenge was created to accelerate the development of disruptive, patient-centric and connected health solutions, from Partners HealthCare employees and clinical faculty, to radically improve the lives of patients. To bridge … the lives of patients. Support this year was provided by Teva Pharmaceuticals, ObjectFrontier Software, [email protected], MedTech Boston and General Assembly. Partners Connected Health Partners Connected Health , at Partners HealthCare, is leveraging information technology – mobile …

MultiCare Health System

MedTech Growing on Emerging Markets, M&A: Stocks to Buy | Zacks | 10/26/2017

… of Codman Neurosurgery business from Johnson & Johnson for $1.045 billion. This apart, in September, Cooper entered into an agreement with Teva Pharmaceutical **Industries to acquire the global rights and business of Teva’s PARAGARD Intrauterine Device … CYH divested Rockwood Health System and the associated assets to **MultiCare Health System. Key Picks from the Space Among the medical product stocks, Terumo Corporation ( TRUMY - Free Report ) , sporting a Zacks Rank 1 (Strong Buy …

Health Net

40 GI company developments in 2019 | Becker’s ASC Review | 12/23/2019

Here is what 40 gastroenterology-focused companies did in 2019: Gastrologix and the Digestive Health Network developed GastroAssure, a medical professional liability insurance platform for independent gastroenterology-focused practices. Takeda trimmed down its debt from … Health subsidiary Salix Pharmaceuticals settled an intellectual property case against Teva Pharmaceuticals over Salix’s ulcerative colitis drug Apriso. Artificial intelligence device-maker NinePoint Medical received FDA approval for its NvisionVLE Imaging System. Gastroenterology-focused pharmaceutical …

Global Testicular Cancer Drugs Market 2019-2023 | Evolving Opportunities with Baxter and Bristol-Myers Squibb | Technavio | Business Wire | 12/19/2019

… Health Network, Testicular Cancer Society, ChapCare, and Testicular Cancer Foundation has further boosted the growth of testicular cancer drugs market in North America. Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform Major Five Genetic Testing Companies: Baxter, Bristol-Myers Squibb, Eli Lilly, Pfizer, and Teva Pharmaceutical are among the vendors who have a strong position in the global market. Baxter …

Cigna

WALL STREET PLUNDERS - 6 WALL STREET COMPANIES KEPT AMERICAN ADDICTED TO OPIOID AND RAKED IN THE OBSCENE PROFITS - The companies, including Johnson & Johnson and McKesson Corporation, received subpoenas from Brooklyn prosecutors. | 11/28/2019

… six companies disclosed in recent regulatory filings that they received grand jury subpoenas from federal prosecutors in Brooklyn: Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Mallinckrodt PLC, Amneal Pharmaceuticals Inc., AmerisourceBergen Corporation and McKesson Corporation. Sign … policies 2007 2017 Change Anthem $ 87.73 $ 225.01 ↑ 157% 40.8 million Cigna $ 53.73 $ 203.09 ↑ 278% 11 million Humana $ 75.31 $ 248.07 ↑ 229% 13 million UnitedHealthcare $ 58.20 $ 220.46 ↑ 279% 41.6 million Centene $ 6.86 $ 50.44 ↑ 635% 14 million Molina …

Health stocks shine on Wall Street as Medicare for All shows signs of slippage. | 10/28/2019

… end private insurance. But with public support waning for a single-payer system, private insurers got a boost last week. Cigna Corp. and UnitedHealth Group Inc. both rocketed 10%, and Humana Inc. jumped 9%. Here … to multiple opioid lawsuits involving Endo. Drugmakers Johnson & Johnson and Teva Pharmaceutical are reportedly offering multibillion-dollar settlements in opioid cases. Drug wholesale distributors AmerisourceBergen, Cardinal Health, and McKesson are also negotiating potential settlements. A …

Humana

WALL STREET PLUNDERS - 6 WALL STREET COMPANIES KEPT AMERICAN ADDICTED TO OPIOID AND RAKED IN THE OBSCENE PROFITS - The companies, including Johnson & Johnson and McKesson Corporation, received subpoenas from Brooklyn prosecutors. | 11/28/2019

… six companies disclosed in recent regulatory filings that they received grand jury subpoenas from federal prosecutors in Brooklyn: Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Mallinckrodt PLC, Amneal Pharmaceuticals Inc., AmerisourceBergen Corporation and McKesson Corporation. Sign … 225.01 ↑ 157% 40.8 million Cigna $ 53.73 $ 203.09 ↑ 278% 11 million Humana $ 75.31 $ 248.07 ↑ 229% 13 million UnitedHealthcare $ 58.20 $ 220.46 ↑ 279% 41.6 million Centene $ 6.86 $ 50.44 ↑ 635% 14 million Molina $ 25.80 $ 76.68 ↑ 197% 3.5 million Wellcare …

7 Stocks the Vanguard Health Care Fund Keeps Buying | Yahoo News | 11/7/2019

… 3.76% of outstanding shares, followed by John Paulson (Trades, Portfolio) with 2.13% and First Pacific Advisors (Trades, Portfolio) with 1.18%. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) The Health Care Fund increased its holding by 15.79 … 1.65% and Jim Simons (Trades, Portfolio)’ Renaissance Technologies with 0.90%. Humana Inc. (NYSE:HUM) In the second quarter, the fund increased its position by 52.48% and then boosted it by 33.52% in the third quarter …

Aetna

Consequences | 11/27/2019

… pharmaceutical companies have had in the opioid epidemic. Companies that revealed that they have been subpoenaed in the investigation include: Teva Pharmaceutical Industries, Mallinckrodt, Johnson & Johnson, Amneal Pharmaceuticals, AmerisourceBergen, and McKesson. The international trade deficit … management at the health care company, which purchased health insurer Aetna last year for $70 billion. Alibaba’s Hong Kong-listed stock jumped 7% on its blockbuster debut. The shares trading under auspicious ticker “9988” are …

First Edition: August 8, 2019 | Kaiser Health News | 8/8/2019

… at $57.65, while the broader market was down about 0.5%. (8/7) The Wall Street Journal: CVS Boosts Profit Outlook As Aetna Deal Starts To Pay Off The tone Wednesday was a change from early this … angst over drug companies facing opioid litigation risk. Generics manufacturer Teva Pharmaceutical Industries TEVA 3.26% was the latest to experience that. Sales of $4.3 billion and adjusted earnings of 60 cents a share both topped …

Molina Healthcare

U.S. STOCKS ON THE MOVE-Healthcare stocks, Iron Mountain, oil companies - Nasdaq.com | 7/11/2019

… Corp : up 1.4% Cigna Corp : up 9.9% Cardinal Health Inc : up 1.7% Humana Inc : up 4.1% Centene Corp : up 3.6% Molina Healthcare Inc : up 3.6% Wellcare Health Plans Inc : up 2.1% Eli Lilly and Co … after update on tender offer pricing Mylan NV : down 0.9% Teva Pharmaceutical Industries Ltd : down 2.5% Allergan plc : down 0.2% Short interest on Mylan, Teva at year high as of end June Iron Mountain Inc …

Earnings Scheduled For November 2, 2017 | MSN | 11/2/2017

… Arrow Electronics, Inc. (NYSE: ARW) is estimated to report quarterly earnings at $1.81 per share on revenue of $6.57 billion. Teva Pharmaceutical **Industries Ltd (ADR) (NYSE: TEVA) is projected to report quarterly earnings at $1.06 … earnings at $0.89 per share on revenue of $1.10 billion. **Molina Healthcare, Inc. (NYSE: MOH) is estimated to post quarterly earnings at $0.12 per share on revenue of $4.98 billion. Pandora Media Inc (NYSE: P …

Anthem Blue Cross

MedMen’s 3 New Year’s Resolutions for Health Care Companies Producing Videos | PRWeb | 1/8/2018

Anthem Blue Cross, Boston Scientific, Secure Horizons, Edwards Lifesciences, Blue Cross Blue Shield of North Carolina, Medtronic, UniCare, Natrol Melatonin, Freedom Innovations, Beckman Coulter, Teva Pharmaceuticals, South Coast Medical Center and Ziering Medical, to name a few. Simple, Affordable, Impactful “Our videos are a simple, affordable, impactful way for clients to position their brand and, in so doing, leverage their products and services for greater ROI,” stated Smith. MedMen’s staff …

Proposed Tax Law Demands Health Care Marketers Gain a Stronger Competitive Edge | PRWeb | 12/13/2017

Anthem Blue Cross, Boston Scientific, Secure Horizons, Edwards Lifesciences, Blue Cross Blue Shield of North Carolina, Medtronic, UniCare, Natrol Melatonin, Hoag Hospital, Freedom Innovations, Beckman Coulter, Teva Pharmaceuticals, South Coast Medical Center and Ziering Medical, to name a few. Simple, Affordable, Impactful “Our videos are a simple, affordable, impactful way for medical clients to position their brand, and in so doing, leverage their products and services for greater ROI,” stated …

Laura Wood

Global Epinephrine Market Insights, 2019-2027 - Presents the Market Shares of Leading Players Mylan and Teva Pharmaceutical Industries - ResearchAndMarkets.com | Business Wire | 3/31/2020

… demand from schools. Mylan has been a dominant player in the epinephrine auto-injector market since long. However, in 2018, Teva Pharmaceutical received the generic version FDA approval for its epinephrine auto-injector. This approval … about this report visit https://www.researchandmarkets.com/r/6rtu84 Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call …

Donald Trump

Sun Pharma’s U.S. Unit Donates Hydroxychloroquine Sulfate Tablets in Fight Against Coronavirus | U.S. News & World Report | 3/27/2020

… 19, the respiratory illness caused by the coronavirus, but is currently under investigation as a possible treatment option. U.S. President Donald Trump last week touted the malaria drugs, and the country’s Health and Human Services … from the disease. Several drugmakers, including Novartis, Bayer AG and Teva Pharmaceuticals Industries Ltd, have also donated doses of malaria drugs. “We are working with supply chain partners and wholesalers to help ensure swift delivery …

George D. Yancopoulos

EYLEA® (aflibercept) Injection Reduced Risk of Developing Vision-Threatening Events by 75% After Two Years in Patients with Diabetic Retinopathy | PR Newswire | 2/9/2020

… will hopefully build on this standard-of-care therapy and represents our ongoing commitment to ophthalmologic research and development,” said George D. Yancopoulos , M.D., Ph.D., President and Chief Scientific Officer at Regeneron. “We are eager … or collaboration agreement, including Regeneron’s agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with …

Warren Buffett

Global Skin Patch Market Report by Industry Analysis, Size, Share, CAGR Status, Growth Opportunities and Forecast 2025 - GuruFocus.com | 2/6/2020

Teva Pharmaceutical Industries Luye Pharma Group Hisamitsu Pharmaceutical Mundipharma International Purdue Pharma Warren Buffett Recent Buys Warren Buffett’s Current Portfolio This Powerful Chart Made Peter Lynch 29% A Year For 13 Years Get a sample copy of the report @ http://www.360marketupdates.com/enquiry/request-sample/14729496 The global Skin Patch market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at …

Warren Buffet

Global Skin Patch Market Report by Industry Analysis, Size, Share, CAGR Status, Growth Opportunities and Forecast 2025 - GuruFocus.com | 2/6/2020

Teva Pharmaceutical Industries Luye Pharma Group Hisamitsu Pharmaceutical Mundipharma International Purdue Pharma Warren Buffett Recent Buys Warren Buffett’s Current Portfolio This Powerful Chart Made Peter Lynch 29% A Year For 13 Years Get a sample copy of the report @ http://www.360marketupdates.com/enquiry/request-sample/14729496 The global Skin Patch market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at …

Mike Hunter

OKC students learn damage, disposal of prescription drugs | 1/31/2020

… medical centers in the Oklahoma City metro area have disposal sites registered with the Drug Enforcement Administration . Oklahoma Attorney General Mike Hunter commended the Capitol Hill students for taking the drug safety course and Walmart … state has reached settlements with Purdue Pharma for $270 million, Teva Pharmaceuticals for $85 million and Endo Pharmaceuticals for $8.75 million for their alleged roles in contributing to opioid addiction and death in Oklahoma. “In …

William Tong

Why Teva Investors Should Keep Their Hands on the Pause Button | 1/28/2020

… 2020 By Tezcan Gecgil , InvestorPlace Contributor Jan 28, 2020, 10:40 am EST January 28, 2020 Over the past four months, Teva Pharmaceutical (NASDAQ: TEVA ) stock has gone up from around $6.5 to a recent high … the illegal actions. The case filed by Connecticut Attorney General William Tong claimed that unlike the usual dynamics of generics marketplace, “prices for hundreds of generic drugs have risen – while some have skyrocketed, without explanation …

David Maris

Wells Fargo Reaffirms Their Hold Rating on Mallinckrodt (MNK) | 1/22/2020

David Maris maintained a Hold rating on Mallinckrodt ( MNK ) today. The company’s shares closed last Monday at $6.04. Maris has 0 stars on 0-5 star ranking scale with an average return of -4.9% and a 39.0% success rate. Maris covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Amphastar Pharmaceuticals, and Bausch Health Companies. The word on The Street in general, suggests a Hold analyst consensus rating …

Scott Gottlieb

Celltrion’s Ambitious Biosimilar Plan: 10 Launches in 10 Years | BioSpace | 1/20/2020

… lower-priced drugs. In July, the U.S. Food and Administration (FDA) rolled out its Biosimilars Action Plan. Then-FDA Commissioner Scott Gottlieb noted that less than 2% of Americans use biologics, but they account for … South Korea’s Samsung Bioepis, as well as Amgen, Pfizer and Teva Pharmaceutical. Celltrion entered the biosimilar market in 2013 with a biosimilar version of Johnson & Johnson and Merck’s Remicade (infliximab), marketed as Remsima. There were …

Dan Polster

Status hearing for Huntington, Cabell federal opioid cases set for Jan. 27 in Charleston | 1/20/2020

… Faber issued the order after the U.S. Judicial Panel on Multi-District Litigation agreed with Cleveland-based U.S. District Judge Dan Polster about sending the cases back to West Virginia for trial. Polster, who is … for San Francisco, Chicago and Cherokee Nation.” In October, drugmaker Teva Pharmaceuticals settled with two Ohio counties just before a trial was set to begin in Cleveland. There was much discussion about other cases settling …

Thad Balkman

Here’s What Happened To $829 Million Oklahoma Was Awarded To Treat Opioid Addiction | 1/17/2020

… each company or group. Johnson & Johnson At the conclusion of a seven week-long trial in Norman, Oklahoma District Judge Thad Balkman found Johnson & Johnson liable for helping fuel the state’s opioid crisis and ordered … date after a board has been formed to allocate it. Teva Pharmaceuticals The Israel-based pharmaceutical company became the second to settle, just days before they were headed to trial. Teva agreed to an $85 …

Umer Raffat

Evercore ISI Maintains Their Hold Rating on Amgen (AMGN) | 1/13/2020

Umer Raffat from Evercore ISI maintained a Hold rating on Amgen ( AMGN ). The company’s shares closed last Monday at $238.26, close to its 52-week high of $244.99. According to TipRanks.com , Raffat is a 4-star analyst with an average return of 9.1% and a 69.7% success rate. Raffat covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Phathom Pharmaceuticals, and Pieris Pharmaceuticals. Amgen has an analyst …

Nancy Pelosi

Oklahoma reaches $8.75 million settlement with opiate maker | 1/10/2020

… state also reached pre-trial settlements totaling $355 million with two other drugmakers: Oxycontin-maker Purdue Pharma and Israeli-owned Teva Pharmaceuticals. Read More Dollar General ‘DGX’ store opens in downtown Tulsa It’s not quite … to send impeachment articles to Senate next week House Speaker Nancy Pelosi told Democrats on Friday that the House is likely to vote next week to officially send a pair of impeachment articles against President …

Sara Peerun

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… new report today you stay better informed and ready to act. To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-biomarkers … US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene Trans-Hit Biomarkers Tufts Center for the Study of Drug …

Terri White

J&J’s Pay Out Amount is Reduced Due to “Math Error” | 12/4/2019

… proven that J&J engaged in misleading marketing about the benefits of painkillers.” During the trial, Oklahoma mental health commissioner Terri White, said J&J’s insistence that it has zero responsibility for the state’s opioid … pre-trial settlements by the drugmakers Purdue Pharma LP and Teva Pharmaceutical Industries Ltd.” To this, Balkman responded that the state does not allow for such credits. As it prepares to face a slew of …

Melinda Gates

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Scientific Bavarian Nordic Bayer Bayer Healthcare Baylor College of Medicine Beckman Coulter Beijing Genomics Institute (BGI) Besins Healthcare Bill and Melinda Gates Foundation Biocon Biomnis Biotech Inc BL&H Bluebird Bio BMV Medica Boston Scientific … Pharmaceutical SynteractHCR Takeda Pharmaceutical Tec-Pharma Telenatal Tesaro Tessa Therapeutics Teva Pharmaceutical Industries Teva Pharmaceuticals USA Theramex TherapeuticsMD Thermo Fisher Scientific Transgene Trimel Pharmaceuticals Trivector Biomed Trophogen twoXAR Unified Women’s Clinical Research University College Dublin …

John Kapoor

Reuters Health News Summary | Yahoo News | 11/28/2019

… received subpoenas from the U.S. Attorney’s office in the Eastern District of New York as part of the investigation: drugmakers Teva Pharmaceutical Industries Ltd , Mallinckrodt Plc, Johnson & Johnson and Amneal Pharmaceuticals Inc, and distributor McKesson … evidence prosecutors presented at trial did not support finding that John Kapoor and the others intended for doctors to prescribe the drug, Subsys, to patients who did not need it. Massachusetts adopts tough ban on …

Alex Azar

POLITICO Playbook: Will Trump participate now? - POLITICO | 11/27/2019

… RACHANA PRADHAN, ADAM CANCRYN and DAN DIAMOND: “Clashes among top HHS officials undermine Trump agenda”: “President Donald Trump’s health secretary, Alex Azar, and his Medicare chief, Seema Verma, are increasingly at odds, and their feuding … attorney’s office in the Eastern District of New York: drugmakers Teva Pharmaceutical Industries Ltd., Mallinckrodt PLC, Johnson & Johnson and Amneal Pharmaceuticals Inc. and distributors AmerisourceBergen Corp. and McKesson Corp. People familiar with the matter said …

Bernie Sanders

POLITICO Playbook: Will Trump participate now? - POLITICO | 11/27/2019

… the poll. South Bend Mayor Pete Buttigieg surged into second, rising 6 points to 16 percent, with Warren and Sen. Bernie Sanders not far behind at 14 and 13 percent, respectively.” POLITICO … The poll … More … attorney’s office in the Eastern District of New York: drugmakers Teva Pharmaceutical Industries Ltd., Mallinckrodt PLC, Johnson & Johnson and Amneal Pharmaceuticals Inc. and distributors AmerisourceBergen Corp. and McKesson Corp. People familiar with the matter said …

William Barr

First Edition: November 27, 2019 | Kaiser Health News | 11/27/2019

… task force on missing and slain American Indians and Alaska Natives. The task force will be overseen by Attorney General William Barr and Interior Secretary David Bernhardt. It will develop protocols to apply to new … District of New York as part of the investigation: drugmakers Teva Pharmaceutical Industries Ltd, Mallinckrodt Plc, Johnson & Johnson and Amneal Pharmaceuticals Inc, and distributor McKesson Corp, regulatory filings showed. (11/26) The Wall Street Journal: Federal …

Pete Buttigieg

POLITICO Playbook: Will Trump participate now? - POLITICO | 11/27/2019

… saw him surrender his solid frontrunner status, climbing 3 points to earn 24 percent in the poll. South Bend Mayor Pete Buttigieg surged into second, rising 6 points to 16 percent, with Warren and Sen … attorney’s office in the Eastern District of New York: drugmakers Teva Pharmaceutical Industries Ltd., Mallinckrodt PLC, Johnson & Johnson and Amneal Pharmaceuticals Inc. and distributors AmerisourceBergen Corp. and McKesson Corp. People familiar with the matter said …

Chris Christie

Norcross says tax incentive task force has unfairly singled out his business, allies | Politico | 11/18/2019

… a citation for disorderly conduct.” The multibillion-dollar tax incentive program was expanded six years ago under former Republican Gov. Chris Christie — a key ally of Norcross despite their different political parties — and lasted five … bribery scandal. Norcross said the company was minor compared to Teva Pharmaceuticals, which was awarded a $40 million incentive under the Murphy administration and has faced a foreign bribery scandal and opioid-related lawsuits . “A …

Michael McClellan

IBI- Teva CEO successfully navigating stormy seas | 11/17/2019

… says, “Kare Schultz now has a safe harbor in view.” The positive aspects of the third quarter financial report that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA ; TASE: TEVA ) published last Thursday - improved cash flow, upgraded … the publication of its reports on Thursday, outgoing Teva CFO Michael McClellan said that Teva was examining the conditions, and would make a bond issue if it appeared logical. He added that the company was …

Jackie Fortier

Oklahoma Judge Shaves $107 Million Off Opioid Decision Against Johnson & Johnson | 11/15/2019

… Balkman listens to statements from the defense during a hearing last month in Norman, Okla. Nov 15, 2019 Colin Dwyer, Jackie Fortier Updated at 3:55 p.m. ET A global megacorporation best known for Band-Aids … state’s pretrial settlements with fellow drug companies Purdue Pharma and Teva Pharmaceuticals , which would have reduced the judgment against them by another $355 million. In his judgment Friday, Balkman rejected that proposal. In a statement …

Richard Sackler

City Hall Notebook: Partisan politics reach local election - News - telegram.com - Worcester, MA | 11/12/2019

… lawsuit include Purdue Pharma, L.P. d/b/a Purdue Pharma (DE) Limited Partnership; Purdue Pharma Inc.; Purdue Frederick Co. Inc.; Teva Pharmaceuticals USA Inc.; Cephalon Inc.; Collegium Pharmaceutical Inc.; Johnson & Johnson; Janssen Pharmaceuticals Inc.; Ortho … McKesson Corp.; AmerisourceBergen Drug Corp.; Cardinal Health Inc.; John Kapoor; Richard Sackler; Theresa Sackler; Kathe Sackler; Jonathan Sackler; Mortimer D.A. Sackler; Beverly Sackler; David Sackler; Ilene Sackler Lefcourt; CVS Pharmacy Inc.; Rite Aid of Massachusetts …